Time to Benefit of Surgery vs. Targeted Medical Therapy for Patients with Primary Aldosteronism: A Meta-analysis.
Sunil SamnaniIrena CenzerGregory A KlineSei J LeeGregory L HundemerCaitlin McClurgJanice L PasiekaW John BoscardinPaul E RonksleyAlexander A LeungPublished in: The Journal of clinical endocrinology and metabolism (2023)
Surgery is associated with lower all-cause mortality and MACE compared to medical therapy for primary aldosteronism. For most patients, the long-term surgical benefits outweigh the short-term perioperative risks.
Keyphrases
- minimally invasive
- coronary artery bypass
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- surgical site infection
- prognostic factors
- patients undergoing
- peritoneal dialysis
- cardiac surgery
- human health
- risk assessment
- acute coronary syndrome
- coronary artery disease
- climate change